Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Knight Therapeutics Inc
T.GUD
Alternate Symbol(s):
KHTRF
Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select...
international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:GUD)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(8)
•••
wofats
X
View Profile
View Bullboard History
Comment by
wofats
on Mar 21, 2024 11:36am
RE:RE:New Press Release - Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results
You said everything is bad This? Revenues were $328,199, an increase of $34,636 or 12% over prior year. Revenues excluding IAS 29 were $343,138, an increase of $51,368 or 18% over
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Mar 21, 2024 7:30am
New Press Release - Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results
Achieved Record Annual Revenues and EBITDA MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended...
read article.
Freegold Intersects 3.62 g/t Au over 42m and 1.23 g/t Au over 170.7m
posted Nov 13, 2024 9:00am by
Freegold Ventures Limited
-
|
Four specific holes were drilled to facilitate additional metallurgical testing and were strategically designed to collect representative material from the deposit while improving infill drilling efforts. Approximately ~2,400 meters of ½ PQ core (~ 20 tonnes) have been shipped to BaseMet Labs in Kamloops, BC, where a comprehensive suite of metallurgical testing is currently underway ...read more
(0)
•••
Stockcadman
X
View Profile
View Bullboard History
Post by
Stockcadman
on Mar 20, 2024 6:42pm
Earnings
Let's see if they can show us a bit of growth for 2024. The stock is so depressed here trading at 5x EV/EBITDA.
(152)
•••
longrun86
X
View Profile
View Bullboard History
Comment by
longrun86
on Mar 19, 2024 6:52pm
RE:Next Earnings - 2024/03/21
The fun begins! I am expecting that some fairly material insights into FY2024 and especially regarding the revenue and operating margin growth. I am also hopeful that they will be able to
...more
(29)
•••
Sinister
X
View Profile
View Bullboard History
Post by
Sinister
on Mar 19, 2024 4:05pm
Next Earnings - 2024/03/21
So my fellow investors, what is your prediction and thoughts on the next earning? (Just for fun) I preddict that it wont change that much. What will really change the price is when those medication
...more
(17)
•••
GoldenInvestor
X
View Profile
View Bullboard History
Post by
GoldenInvestor
on Mar 15, 2024 10:58am
Morgan Stanley CIO on AI & drug discovery
Morgan Stanley CIO on CNBC speaking to how AI can help benefit healthcare via drug discovery. Once drugs are discovered, then they have to be produced. With 3 manufacturing
...more
(8)
•••
wofats
X
View Profile
View Bullboard History
Comment by
wofats
on Mar 14, 2024 10:27pm
RE:purchase one week out from results
Maybe they are covering some short positions. There is over 3 million. Makes money both ways.
(17)
•••
GoldenInvestor
X
View Profile
View Bullboard History
Post by
GoldenInvestor
on Mar 14, 2024 9:14pm
purchase one week out from results
Armoyan purchased of approx $700k in GUD shares - why would that be?
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Mar 14, 2024 7:30am
New Press Release - Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call
MONTREAL, March 14, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2023 financial results on Thursday, March 21, 2024 prior to market opening. Following the...
read article.
(8)
•••
wofats
X
View Profile
View Bullboard History
Comment by
wofats
on Mar 13, 2024 6:01pm
RE:RE:BNN next week
of Issuer Holder: Armco Alberta Inc. (Control or Direction) Common Shares 10 - Acquisition or disposition in the public market $402,150 +76,600 vol
...more
(1869)
•••
Possibleidiot01
X
View Profile
View Bullboard History
Comment by
Possibleidiot01
on Mar 12, 2024 2:28pm
RE:BNN next week
stockchase.com, Jason Donville DON'T BUY Knight Therapeutics(GUD-T) 12/03/2024 Years ago, they bought a major company that he owned a lot of
...more
(13)
•••
gudisgood
X
View Profile
View Bullboard History
Comment by
gudisgood
on Mar 12, 2024 6:10am
RE:BNN next week
Interesting! In the short-term, our results and financial situation will be significantly influenced by a couple things: 1) Will the MOH contracts continue coming in? This will significantly affect
...more
(8)
•••
wofats
X
View Profile
View Bullboard History
Post by
wofats
on Mar 09, 2024 4:59pm
BNN next week
Jason Donville This was an analyst who started talking about Paladin Labs in the early days of the stocks rise 2008 or 2009 I believe . Here is a link to some info on his philosophy
...more
(152)
•••
longrun86
X
View Profile
View Bullboard History
Comment by
longrun86
on Mar 07, 2024 10:01am
RE:Raymond James’ Rahul Sarugaser bumped his price target
Analysts make me laugh. If the analyst really believes in the statement they put out regarding Knight as the pre-eminent distributor of phamaceuticals, raising your price target by $0.50 is somewhat
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Explained: The Psychology of Options Trading with Practical Tips
Meet the Top 5 Best Online Brokerages in Canada
Have you held units of a TD mutual fund (other than through a discount broker)? Learn more.
Geodrill Generates Revenue of $34.1M, a 13% Increase Compared to $30.3M for Q3-2023
Gold, growth and sustainability in focus for this resource company
Star Diamond Corporation Announces Third Quarter 2024 Results
Coppernico Drills 19 Meters of 0.50% Copper in First 5 Holes and Applies for Additional Permits